Viatris, the pharmaceutical manufacturer, has initiated a nationwide recall for its widely prescribed anxiety medication, Xanax. This action, taken last month, stems from concerns over "failed dissolution specifications," which could impair the drug's proper breakdown and release within the body.
Understanding the Recall Details
The recall specifically targets Xanax XR, alprazolam extended-release tablets in 3 mg doses, packaged in 60-tablet bottles and available by prescription only. The affected lot number is 8177156, with an expiration date set for February 28, 2027. According to the Food and Drug Administration, Viatris did not issue a formal press release but distributed notification letters to inform stakeholders.
FDA Classification and Implications
Last week, the FDA escalated the recall to a Class II classification. This designation indicates that the recalled pills might lead to temporary or medically reversible adverse health effects, though the likelihood of serious consequences remains low. The classification underscores potential risks such as reduced therapeutic effectiveness if the medication fails to dissolve correctly, thereby not releasing the drug at the intended rate.
About Xanax and Its Uses
Xanax is a benzodiazepine, a class of depressants that slow the central nervous system. Primarily prescribed for anxiety disorders, it can also alleviate muscle spasms and reduce seizures, as noted by the Drug Enforcement Administration. Patients are cautioned against exceeding prescribed dosages or sharing the medication with others, as highlighted on the official Xanax website.
Consumer Actions and Additional Recalls
Individuals currently using Xanax are advised to contact Viatris customer relations at (800) 796-9526 or via email at customer.service@viatris.com for further guidance. In a related development, consumers should also inspect their medicine cabinets for cough drops recently recalled. Xiamen Kang Zhongyuan Biotechnology Co., Ltd., based in China, recalled 15 cough drop products across the U.S. last month, following an FDA recommendation based on inspection observations that may impact product quality. This recall was similarly classified as Class II last week.
The Independent has reached out to Viatris for additional comments on the recall, but no response has been received at this time. This situation highlights ongoing vigilance in pharmaceutical safety and regulatory oversight to protect public health.
